Rationale and Comments

CA-125 and ultrasound in low-risk, asymptomatic women have not led to diagnosis of ovarian cancer in earlier stages of disease or reduced ovarian cancer mortality. False-positive results of either test can lead to unnecessary procedures, which have risks of complication.

Sponsoring Organizations

• Society of Gynecologic Oncology

Sources

• U.S. Preventive Services Task Force

Disciplines

• Gynecologic
• Oncologic
• Preventive Medicine

References

• Barton MB, Lin K. Screening for ovarian cancer: Evidence update for the U.S. Preventive Services Task Force reaffirmation recommendation statement [Internet]. Rockville (MD); 2012 Apr. Agency for Healthcare Research and Quality; AHRQ Publication No. 12-05165–EF3. Available from: http://www.uspreventiveservicestaskforce.org/uspstf12/ovarian/ovarcancerrs.htm.
  
• Buys SS, Partridge E, Black A, Johnson CC, Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B, Crawford ED, Church TR, Andriole GL, Weissfeld JL, Fouad MN, Chia D, O’Brien B, Ragard LR, Clapp JD, Rathmell JM, Riley TL, Hartge P, Pinsky PF, Zhu CS, Izmirlian G, Kramer BS, Miller AB, Xu JL, Prorok PC, Gohagan JK, Berg CD; PLCO Project Team. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening randomized controlled trial. JAMA. 2011 Jun 8;305(22):2295-303.
  
• American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. The role of the obstetrician-gynecologist in the early detection of epithelial ovarian cancer. Committee Opinion No. 477. Obstet Gynecol. 2011 Mar;117(3):742-6.